Pimozide-d4

Pimozide-d4

• CAS Number: 1803193-57-8
• UNSPSC Description: Pimozide-d4 is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].
• Target Antigen: Adrenergic Receptor; Dopamine Receptor; STAT
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;JAK/STAT Signaling;Neuronal Signaling;Stem Cell/Wnt
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Cancer; Endocrinology; Neurological Disease
• Purity: 98.0
• Solubility: 10 mM in DMSO
• Smiles: O=C1NC2=CC=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=C([2H])C([2H])=C(F)C([2H])=C5[2H])CC3
• Molecular Weight: 465.57
• References & Citations: [1]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256(2):141-7.|[2]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9(8):3853-3866. eCollection 2017.|[3]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12): 3421-3429.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: Phase 4